jrnl3811

Publication Venue For

  • Osteoporosis Pathophysiology, Epidemiology, and Screening in Rheumatoid Arthritis.  21. 2019
  • Rituximab in ANCA-Associated Vasculitis.  19. 2017
  • Infections With Biologics in Rheumatoid Arthritis and Related Conditions: a Scoping Review of Serious or Hospitalized Infections in Observational Studies.  18. 2016
  • Racial/Ethnic Disparity in Rates and Outcomes of Total Joint Arthroplasty.  18. 2016
  • Genetic Defects in Cytolysis in Macrophage Activation Syndrome.  16. 2014
  • Pneumocystis jirovecii Pneumonia in Patients Receiving Tumor-Necrosis-Factor-Inhibitor Therapy: Implications for Chemoprophylaxis.  16. 2014
  • Vaccinations for rheumatoid arthritis.  16. 2014
  • Infectious complications in juvenile idiopathic arthritis.  15. 2013
  • Racial and gender disparities among patients with gout.  15. 2013
  • What is the background incidence of malignancy in children with rheumatic disease?.  15. 2013
  • Managing macrophages in rheumatoid arthritis by reform or removal.  14:445-454. 2012
  • From fracture risk prediction to evaluating fracture patterns: Recent advances in the epidemiology of osteoporosis.  14:205-211. 2012
  • Measurement of erythrocyte methotrexate polyglutamate levels: Ready for clinical use in rheumatoid arthritis?.  12:342-347. 2010
  • Quality-of-life measurements in multiethnic patients with systemic lupus erythematosus: Cross-cultural issues.  12:237-249. 2010
  • Bone changes and fracture risk in individuals infected with HIV.  12:163-169. 2010
  • The societal burden of osteoporosis.  12:186-191. 2010
  • Uric acid and hypertension: Cause or effect?.  12:108-117. 2010
  • Quality of life and quality of care for patients with gout.  11:154-160. 2009
  • Tumor necrosis factor inhibitors and infection complications.  10:383-389. 2008
  • Update on pathogenic mechanisms of systemic necrotizing vasculitis.  10:430-435. 2008
  • Calcium and vitamin D: Skeletal and extraskeletal health.  10:110-117. 2008
  • Improving quality of care in osteoporosis: Opportunities and challenges.  10:123-130. 2008
  • The use of zoledronic acid for osteoporosis..  10:89-91. 2008
  • Therapeutic advances in calcium and vitamin D for osteoporosis..  10:90-91. 2008
  • Denosumab in postmenopausal women with low bone mineral density..  9:48. 2007
  • Ibandronate injections in postmenopausal women with osteoporosis..  9:47. 2007
  • New directions in osteoporosis therapy: Intravenous ibandronate and denosumab.  9:47-49. 2007
  • Not just calcium and vitamin D: Other nutritional considerations in osteoporosis.  9:85-92. 2007
  • Uveitis: Advances in understanding of pathogenesis and treatment.  8:260-266. 2006
  • Low-dose prednisolone in early rheumatoid arthritis.  8:48-49. 2006
  • The use of low-dose glucocorticoids for the treatment of early rheumatoid arthritis: What can we learn about bone effects of glucocorticoids from randomized controlled trials?.  8:47-48. 2006
  • Classification of the vasculitides: are they clinically useful?.  7:265-269. 2005
  • Gout treatment: what is evidence-based and how do we determine and promote optimized clinical care?.  7:242-249. 2005
  • Recent advances in the epidemiology of gout..  7:235-241. 2005
  • Update on autoantibodies in rheumatoid arthritis..  6:343-350. 2004
  • Ethnic disparities in patients with systemic lupus erythematosus..  5:364-369. 2003
  • Glucocorticoid use in rheumatoid arthritis..  4:218-225. 2002
  • Polyarteritis nodosa and microscopic polyangiitis: etiologic and diagnostic considerations..  4:75-82. 2002
  • Apoptosis and rheumatoid arthritis: past, present, and future directions..  3:70-78. 2001
  • Use of neuroimaging to understand abnormal pain sensitivity in fibromyalgia..  2:141-148. 2000
  • The genetics of rheumatoid arthritis: influences on susceptibility, severity, and treatment response..  1:164-171. 1999
  • Web alert..  1:89-90. 1999